Abstract:Background: Cluster of Differentiation 93 (CD93) plays an important role in angiogenesis and is considered an important target for inhibiting tumor angiogenesis, but there are currently no therapeutic antibodies against CD93 in the clinic. Thus, we describe the screening of novel nanobodies (Nbs) targeting human CD93 from a phage library of shark-derived Nbs. Methods: Screening and enrichment of phage libraries by enzyme-linked immunosorbent assay (ELISA). Anti-CD93 Nbs were purified by expression in E. coli . The binding affinity of anti-CD93 Nbs NC81/NC89 for CD93 was examined by flow cytometry (FC) and ELISA. The thermal stability of NC81/NC89 was examined by ELISA and CD spectroscopy. Afterward, the anti-angiogenic ability of NC81/NC89 was examined by MTT, wound healing assay, and tube formation assay. The expression level of VE-cadherin (VE-Ca) and CD93 was detected by Western Blot (WB). The binding sites and binding forms of NC81/NC89 to CD93 were analyzed by molecular docking. Results: The anti-CD93 Nbs were screened in a phage library, expressed in E. coli , and purified to >95% purity. The results of FC and ELISA showed that NC81/NC89 have binding ability to human umbilical vein endothelial cells (HUVECs). The results of ELISA and CD spectroscopy showed that NC81/NC89 retained the ability to bind CD93 at 80°C and that the secondary structure remained stable. In vitro , the results showed that NC81 and NC89 significantly inhibited the proliferation and migration of human umbilical vein endothelial cells (HUVECs) as well as tube formation on Matrigel. Western Blot showed that NC81 and NC89 also inhibited the expression of VE-Ca thereby increasing vascular permeability. It was found during molecular docking that the CDR regions of NC81 and NC89 could be attached to CD93 by strong hydrogen bonds and salt bridges, and the binding sites were different. Conclusion: We have successfully isolated NC81 and NC89, which bind CD93, and both Nbs significantly inhibit angiogenesis and increase vascular permeability. These results suggest that NC81 and NC89 have potential clinical applications in angiogenesis-related therapies.

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

FP3: a Novel VEGF Blocker with Anti-Angiogenic and Anti-Tumor Effects.

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

Generation of Scfv Specific to Human Vegfr-3 from the Neutralizing Mab Bdd073

Generation and Characterization of a Novel Human IgG1 Antibody Against Vascular Endothelial Growth Factor Receptor 2

Antitumor Effect of FP3 in a Breast Cancer Xenograft Model.

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding

Inhibition of monoclonal antibodies against extracellular I-IV domains of vascular endothelial cell growth factor receptor KDR on the proliferation EC and formation of chicken embryo blood vessels

Antitumor Effect of FP3 in a Patient-Derived Tumor Tissue Xenograft Model of Gastric Carcinoma Through an Antiangiogenic Mechanism.

Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with Vegfr-3 Sirna Delivered with Pei-Alginate Nanoparticles

Inhibition of Tumor Angiogenesis in Lung Cancer by T4 Phage Surface Displaying Mvegfr2 Vaccine

Soluble Vascular Endothelial Growth Factor Decoy Receptor FP3 Exerts Potent Antiangiogenic Effects.

Antiangiogenic Activities of Anti-Bfgf Monoclonal Antibodies

Screening and construction of nanobodies against human CD93 using phage libraries and study of their antiangiogenic effects

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

A Murine–human Chimeric IgG Antibody Against Vascular Endothelial Growth Factor Receptor 2 Inhibits Angiogenesis in Vitro

Screening and anti-angiogenesis activity of Chiloscyllium plagiosum anti-human VEGFR2 single-domain antibody

A Novel Peptide Specifically Binding to VEGF Receptor Suppresses Angiogenesis in Vitro and in Vivo

Generation and characterization of a human nanobody against VEGFR-2

Phage‐derived Fully Human Antibody Scfv Fragment Directed Against Human Vascular Endothelial Growth Factor Receptor 2 Blocked Its Interaction with VEGF

Angio-3, a 10-Residue Peptide Derived from Human Plasminogen Kringle 3, Suppresses Tumor Growth in Mice Via Impeding Both Angiogenesis and Vascular Permeability